132
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Effect of whole body hyperthermia on radiation therapy of transplanted fibrosarcoma in Swiss mice

Pages 428-438 | Published online: 09 Jul 2009

  • Patil MS, Kaklij GS, Poduval TB, Singh BB. Radioprotective effect of whole body hyperthermia on mice exposed to lethal doses of total body gamma irradiation. Ind. J Exp Biol 1996; 34: 842-844.
  • Shen RN, Hornback NB, Shidnia H, Wu B, Lu L, Broxmeyer HE. Whole body hyperthermia: a potent radioprotector in vivo. Int. J Radiat Oncol Biol Phys 1991; 20: 525-530.
  • Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D, Grosen E, Tiggelaar CL, Spriggs D, Gillis W, DOleire F. Cytokine induction by 41.8°C whole body hyperthermiaCancer Lett 1995; 97: 195-201.
  • Zaidi AK, Patil MS, Bagewadikar RS, Subramanian M, Kaklij GS. Radioprotection by whole body hyperthermia: possible mechanism(s). J Therm Biol 2001.
  • Neta R, Douches SD, Oppenheim JJ. Interleukin-1 is a radioprotector. J Immunol 1986; 136: 2483-2485.
  • Neta R, Stiefel SM, Finkelman F, Herrmann S, AIi Jr N. IL-12 protects bone marrow from and sensitises intestinal tract to ionising radiation. Immunol 1994; 153: 4230-4237.
  • Dalmau SR, Freitas CS, Savino W. Radio- and chemoprotection of bone marrow cells by opposite cell cycle acting cytokines. Leukemia Res 1997; 21: 93-99.
  • Wu SG, Miyamoto T. Radioprotection of intestinal crypts of mice by recombinant human interleukin-1a. Radiat Res 1990; 124: 112-115.
  • Khan WB, Shui C, Ning S, Knox SJ. Enhancement of murine intestinal stem cells survival after irradiation by keratinocyte growth factor. Radiat Res 1997; 148: 248-253.
  • Waravadekar SS, Randive KJ. Biological testing of sulphur isosteres of carcinogenic hydrocarbons. J Nat Cancer Inst 1957; 18: 555-559.
  • Ray PK, Thakur VS, Sundaram K. Antitumour immunity II: viability, tumorigenicity and immunogenicity of neuraminidase treated tumour cells: Effective immunization of animals with a tumour vaccine. J Nat Cancer Inst 1976; 56: 83-87.
  • Kelkar SM, Shenoy MA, Kaklij GS. Antitumour activity of lactic acid bacteria on a solid fibrosarcoma, sarcoma-180 and Ehrlich ascots carcinoma. Cancer Lett 1988; 42: 73-77.
  • Shigejiro H, Herman DS. Effect of fractionation of radiation dose on skin contraction and skin reaction of Swiss mice. Radial 1972; 103: 431-437.
  • Streffer C, Van Beuningen D, Zamboglou N. Cell killing by hyperthermia and radiation by cancer therapy. In: Abe M, Sakamoto K, Phillips TL, eds. Treatment of radioresistant cancer. Amsterdam: Elsevier/North Holland Biomedical, 1979: 55-70.
  • Dewey WC, Freeman ML, Raaphorst GP, Clark EP, Wong RSL, Spiro IF, Tomasovic SP, Denman DL, Coss RA. Cell biology of hyperthermia and radiation. In: Mayn R, Withers HP, eds. Radiation Biology in Cancer Research. New York: Raven Press, 1980: 589-621.
  • Streffer C, Van Beuningen D. The biological basis for tumour therapy by hyperthermia and radiation. Recent Results Cancer Res 1987; 104: 24-70.
  • Bisht KS, Uma DP. Hyperthermia in cancer research: current status. Ind J Exp Biol 1996; 34: 1183-1189.
  • Abe M, Hiraoka M. Localized hyperthermia in cancer therapy: review. Int J Radiat Biol 1985; 47: 347-359.
  • Moffat FL, FaIk RE, Laing D, Ketcham AS, FaIk JA. Hyperthermia for cancer a practical perspective, Sem Surg Oncol 1985; 1: 200-219.
  • Stewart JR. Hyperthermia In: de Vita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology, Philadelphia: JB Lippincott, 1985: 2246-2256.
  • Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Biophys 1989; 16: 535-549.
  • Raaphorst GP. Thermal radiosensitization in vitro. In: Urano M, Douple E, eds. Hyperthermia and Oncology, VoI 2, Utrecht VSP, 1989: 17-51.
  • Raaphorst GP. In: Field SB, Hand JW, eds. Fundamental aspects of hyperthermic oncology: An introduction to the practical aspects of clinical hyperthermia, London: Taylor and Francis, 1990: 10-54.
  • Sminia P, Van Der Zee J, Wondergem J, Haveman J. Effect of hyperthermia on the central nervous system: a review. Int J Hyperthermia 1994; 10: 1-30.
  • Kapp DS, Hahn GM, Carlson RW. Principles of hyperthermia In: Holland JF, Frei III E, Bast Jr RC, Kufe DW, Morton DL, eds. Cancer Medicine 4th Edition. Williams and Wilkins, Baltimore, MD, 1997: 479-488.
  • FaIk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001; 70: 1-18.
  • Sakaguchi Y, Makino M, Kaneko T, Stephens LC, Strebe! FR, Danhouser LL, Jenkins GN, Bull JMC. Therapeutic efficacy of long duration low temperature whole body hyperthermia when combined with tumour necrosis factor and carboplatin in rats. Cancer Res 1994; 54: 2223-2227.
  • Toyota N, Strebel FR, Stephens LC, Matsuda H, Bull JMC. Long duration mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis in a metastatic rat mammary adenocarcinoma Int J Hyperthermia 1997; 13: 497-506.
  • Robins HI, Longo WL, Sleeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C. Adjunctive therapy (whole body hyperthermia vs lonidamine) to total body irradiation for the treatment of favourable B cells neoplasms: a report of two pilot clinical trials and laboratory investigations. Int J Radiat Oncol Bio I Phys 1990; 18: 909-920.
  • Robins HI, D'Oleire F, Kutz M, Bird A, Schmitt-Tiggelaar CL, Cohen JD, Spriggs DR. Cytotoxic interaction of tumour necrosis factor melphalan and 41.8C hyperthermia Cancer Lett 1995; 89: 52-62.
  • Robins HI, Rushing D, Kutz M, Tutsch K, Tiggelaar C, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomaniam R, Longo W, Alberti D, d'Oleire F, Qu R, Stewart J, Wilding G. Phase I clinical trial of melphalan (L-PAM) and 41.8°C whole body hyperthermia (WBH) in cancer patients. J Clin Oncol 1997; 15: 158-164.
  • Katschinski D M, Wiedemann GJ, Mentzel M, Longo W, d'Oleire F, Grosen EA, Mulkerin D, Kutz ME, Robins HI. Implications of 41.8°C whole body hyperthermia cytokine induction to cytotoxic therapy and bone marrow transplantatioa Proc Am Ass Cancer Res 1997; 38: 378.
  • Robins HI, Longo WL, Hegander A, Sleeves RA, Flynn B, Schwarte B, Sondel PM. Whole body hyperlhermia combined wilh lolal body irradiation and chemolherapy as a preparative regimen for allogenic bone marrow lransplanlation in a patient wilh Burkitt' s lymphoma. Cancer J 1986; 1: 180-183.
  • Katechinski DM, Wiedemann GJ, Longo W, d'Oleire FR, Spriggs D, Robins HI. Whole body hyperlhermia cytokine induction: a review and unifying hypothesis for myeloprotec tion in lhe selling of cytotoxic lherapy. Cytokine Growth Factor Rev 1999; 10: 93-97.
  • Costine LS, Harwell S, Keng P, Lee F, Rubin P, Siemann D. Inlerleukin-1 alpha stimulates haemopoiesis but nol rumour cell proliferation and protects mice from lethal tolal body irradiation. Int J Radiat Oncol Biol Phys 1991; 20: 447-456.
  • Dorei MJ, Allison AC, Zaghloul MS, Kallman RF. Interleukin-1 protects againsl lethal effects of irradiation of mice but has no effect on tumours in the same animals. Proc Soc Exp Biol Med 1989; 191: 23-29.
  • Kovacs CJ, Harrell JP, Evans MJ, Johnke RM. Absence of inlerleukin Ia radioprolection in tumour-bearing animals: elevated plasma levels of proslaglandin E versus pre-existing primed marrow. J. Leukocyte Biol 1992; 51: 53-58.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.